GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (OTCPK:EVOTF) » Definitions » ROA %

EVOTF (Evotec SE) ROA % : -8.07% (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Evotec SE ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Evotec SE's annualized Net Income for the quarter that ended in Sep. 2024 was $-176.0 Mil. Evotec SE's average Total Assets over the quarter that ended in Sep. 2024 was $2,180.6 Mil. Therefore, Evotec SE's annualized ROA % for the quarter that ended in Sep. 2024 was -8.07%.

The historical rank and industry rank for Evotec SE's ROA % or its related term are showing as below:

EVOTF' s ROA % Range Over the Past 10 Years
Min: -8   Med: 4.26   Max: 11.7
Current: -8

During the past 13 years, Evotec SE's highest ROA % was 11.70%. The lowest was -8.00%. And the median was 4.26%.

EVOTF's ROA % is ranked worse than
73.28% of 1044 companies
in the Drug Manufacturers industry
Industry Median: 1.815 vs EVOTF: -8.00

Evotec SE ROA % Historical Data

The historical data trend for Evotec SE's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE ROA % Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.87 0.49 11.31 -7.57 -3.78

Evotec SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.79 -2.89 -3.70 -17.96 -8.07

Competitive Comparison of Evotec SE's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's ROA % distribution charts can be found below:

* The bar in red indicates where Evotec SE's ROA % falls into.



Evotec SE ROA % Calculation

Evotec SE's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-91.508/( (2391.151+2456.345)/ 2 )
=-91.508/2423.748
=-3.78 %

Evotec SE's annualized ROA % for the quarter that ended in Sep. 2024 is calculated as:

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-175.956/( (2151.661+2209.555)/ 2 )
=-175.956/2180.608
=-8.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data. ROA % is displayed in the 30-year financial page.


Evotec SE  (OTCPK:EVOTF) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-175.956/2180.608
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-175.956 / 820.82)*(820.82 / 2180.608)
=Net Margin %*Asset Turnover
=-21.44 %*0.3764
=-8.07 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Evotec SE ROA % Related Terms

Thank you for viewing the detailed overview of Evotec SE's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.